Advisors

George Peoples, Jr., MD, FACSGeorge Peoples, Jr., MD, FACS Chairman of Phase I DSMB

Dr. Peoples graduated from West Point in 1984 and from Johns Hopkins School of Medicine in 1988. After a surgical internship at Walter Reed Army Medical Center (WRAMC), he completed his surgical training at the Brigham and Women’s Hospital in Boston, MA in 1996. During that time, Dr. Peoples also completed a research fellowship at the Laboratory of Biologic Cancer Therapy at Harvard Medical School.

Dr. Peoples completed a surgical oncology fellowship at MD Anderson Cancer Center in Houston, TX in 1998. He was the previous Chief, Surgical Oncology at WRAMC from 1998-2006 and now serves in that role at Brooke Army Medical Center in San Antonio. He is the Director and Principal Investigator of the Cancer Vaccine Development Program associated with the Uniformed Services University of the Health Sciences and the Deputy Director of the United States Military Cancer Institute.

Dr. Peoples holds 7 patents and 5 INDs and is currently the PI on 7 cancer vaccine clinical trials being conducted at 12 military and civilian sites. He has written extensively on the immune response to cancer.

William E. Gannon, Jr., M.D., M.B.A.William E. Gannon, Jr., M.D., M.B.A. Chief Regulatory Advisor

William E. Gannon, MD, MBA, is the Chief Regulatory Advisor to Oncolix. In addition to receiving his medical training and clinical work at Ross University, Case Western Reserve and George Washington University, Dr. Gannon obtained an M.B.A. in 1988 and has since built a wealth of experience in the management of clinical trials including designing the trials and building operational teams to ensure their successful completion.

Dr. Gannon has over 25 years experience in the regulatory and clinical trials arena. He has held positions in multinational CROs, medical device, biotech and pharmaceutical firms, primarily in the field of cancer. Dr. Gannon has substantial expertise with protocol development and clinical trial management. He has been responsible for numerous regulatory submissions and execution of Phase I through Phase IV trials in the US, Europe and Asia.